Indegene Limited has informed the Exchange about Transcript
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene reported Q4 FY25 revenue of INR 7,556 million, up 12.3% YoY and 4.9% QoQ, with PAT of INR 1,176 million (up 7.2% QoQ). For full year FY25, revenue grew 9.6% to INR 28,393 million and PAT rose 20.8% to INR 4,067 million, while EBITDA margin contracted 90 bps to 19.8% due to higher on-site mix and technology costs. The company ended the year with INR 1,664 crores in cash, acquired UK-based MJL Communications for up to GBP 3.4 million, and announced a 100% dividend (INR 48 crores). Management flagged macro headwinds from US tariffs and FDA layoffs (3,500 staff cut) causing some slowdown in large deal decisions, but highlighted a $5M+ ACV win with a Top 10 EU pharma customer and three mid-tier deals worth $1.5–3M ACV. The GenAI platform 'Cortex' was launched and is being trained with domain experts for life sciences.
Steady FY25 results and a strong cash pile support continued M&A and the newly announced dividend, but margin compression and customer concentration issues (two top-5 customers) may weigh on sentiment. Cautious near-term commentary on macro uncertainty and decision-making delays could keep the stock range-bound in the short term.